AR1001 clinical trials

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

This study is testing a new medicine, AR1001, for people in the early stages of Alzheimer's disease. We want to see if it's safe and helps improve or slow down symptoms compared to a dummy medicine.